MeiraGTx Holdings plc (MGTX)
Largest Insider Buys in Sector
MGTX Stock Price History Chart
MGTX Stock Performance
About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, …
Insider Activity of MeiraGTx Holdings plc
Over the last 12 months, insiders at MeiraGTx Holdings plc have bought $5M and sold $0 worth of MeiraGTx Holdings plc stock.
On average, over the past 5 years, insiders at MeiraGTx Holdings plc have bought $8.6M and sold $4.69M worth of stock each year.
Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC () — $75M.
The last purchase of 1,250,000 shares for transaction amount of $5M was made by PERCEPTIVE ADVISORS LLC () on 2024‑08‑12.
List of Insider Buy and Sell Transactions, MeiraGTx Holdings plc
| 2024-08-12 | 1.25M 1.9341% | $4.00 | $5M | +4.50% | ||||
| 2023-05-05 | 4.35M 8.3577% | $5.75 | $25M | -1.95% | ||||
| 2022-06-03 | CHIEF MEDICAL OFFICER | 6 <0.0001% | $7.89 | $47 | -6.73% | |||
| 2022-05-25 | GENERAL COUNSEL AND SECRETARY | 1,000 0.0022% | $7.94 | $7,940 | -5.28% | |||
| 2021-11-17 | Sale | President and CEO | 30,000 0.0679% | $19.86 | $595,800 | -51.18% | ||
| 2021-11-16 | Sale | President and CEO | 30,000 0.0678% | $19.97 | $599,144 | -51.10% | ||
| 2021-10-20 | Sale | CFO & COO | 41,400 0.0941% | $21.05 | $871,371 | -40.21% | ||
| 2021-10-19 | Sale | CFO & COO | 2,600 0.0062% | $20.07 | $52,182 | -33.88% | ||
| 2021-10-18 | Sale | President and CEO | 60,000 0.1271% | $17.36 | $1.04M | -31.36% | ||
| 2021-10-18 | Sale | Chief Development Officer | 24,000 0.0526% | $17.95 | $430,800 | -31.36% | ||
| 2021-07-20 | Sale | Chief Development Officer | 18,780 0.0419% | $15.06 | $282,827 | -10.03% | ||
| 2021-07-13 | Sale | Chief Development Officer | 5,220 0.0119% | $15.04 | $78,509 | -6.75% | ||
| 2021-06-09 | Sale | President and CEO | 8,306 0.0187% | $15.04 | $124,922 | -6.21% | ||
| 2021-06-08 | Sale | President and CEO | 40,360 0.0917% | $15.02 | $606,207 | -5.14% | ||
| 2021-06-08 | Sale | Chief Development Officer | 10,080 0.0229% | $15.01 | $151,301 | -5.14% | ||
| 2021-06-07 | Sale | President and CEO | 11,334 0.026% | $15.03 | $170,350 | -4.05% | ||
| 2021-06-07 | Sale | Chief Development Officer | 2,084 0.0048% | $15.02 | $31,302 | -4.05% | ||
| 2021-04-30 | Sale | Chief Development Officer | 741 0.0017% | $15.01 | $11,122 | -4.34% | ||
| 2021-04-29 | Sale | Chief Development Officer | 1,405 0.0032% | $15.02 | $21,103 | -4.47% | ||
| 2021-04-28 | Sale | Chief Development Officer | 3,772 0.0087% | $15.14 | $57,108 | -3.43% |
Insider Historical Profitability
| PERCEPTIVE ADVISORS LLC | 12531103 16.1903% | $6.41 | 6 | 0 | <0.0001% | |
| PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 10 percent owner | 6007746 7.7621% | $6.41 | 1 | 0 | +18.44% |
| Seligman Nicole | director | 5000 0.0065% | $6.41 | 1 | 0 | <0.0001% |
| Zeldin Robert K | CHIEF MEDICAL OFFICER | 5000 0.0065% | $6.41 | 1 | 0 | <0.0001% |
| Wollin Robert J | GENERAL COUNSEL AND SECRETARY | 1000 0.0013% | $6.41 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Perceptive Advisors | $68.72M | 17.62 | 11.33M | 0% | +$0 | 0.04 | |
| Johnson & Johnson | $40.31M | 10.33 | 6.64M | 0% | +$0 | 0.94 | |
| Adage Capital Partners Gp L L C | $32.12M | 8.23 | 5.29M | 0% | +$0 | 0.06 | |
| Prosight Management Lp | $24.39M | 6.25 | 4.02M | -0.82% | -$202,816.91 | 6.8 | |
| 683 Capital Management Llc | $15.18M | 3.89 | 2.5M | 0% | +$0 | 1.64 |